Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer

Treatment of castration-resistant prostate cancer (CRPC) is a long-standing clinical challenge. Traditionally, CRPC drugs work by either reducing dihydrotestosterone biosynthesis or blocking androgen receptor (AR) signaling. Here it is demonstrated that AR inhibitor treatment gives rise to a drug-tolerant persister (DTP) state. The thioredoxin/peroxiredoxin pathway is up-regulated in DTP cells. Peroxiredoxin 5 (PRDX5) promotes AR inhibitor resistance and CRPC development. Inhibition of PRDX5 suppresses DTP cell proliferation in culture, dampens CRPC development in animal models, and stabilizes PSA progression and metastatic lesions in patients. Therefore, the study provides a novel mechanism and potential target for the management of castration-resistant prostate cancer. Peroxiredoxin 5 (PRDX5) promotes androgen receptor (AR) inhibitor resistance and castration-resistant prostate cancer (CRPC) development. Inhibition of PRDX5 suppresses drug-tolerant persister (DTP) cell proliferation in culture, dampens CRPC development in animal models, and stabilizes PSA progression and metastatic lesions in patients with the repurposed drug, polaprezinc. Therefore, the study provides a novel mechanism and potential target for the management of CRPC.image